source
- BMS drops $80 million neurodegeneration program after phase-1 resultsBMS announced it will not move forward with a neurodegeneration drug it licensed from Prothena, ending a program it invested $80 million in. The drug, known as BMS-986495 (formerly PRX019), comple…
- Ascletis oral GLP-1 candidate ASC30 meets primary and secondary goals in phase 2 diabetes studyAscletis reported that its oral GLP-1 small‑molecule candidate ASC30 achieved both its primary and secondary endpoints in a phase 2 trial involving 100 patients with type 2 diabetes. The study sho…